株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の皮下投与市場とパイプラインの分析

Subcutaneous Drug Delivery Market & Pipeline Insight

発行 PNS Pharma 商品コード 323522
出版日 ページ情報 英文 1800 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
世界の皮下投与市場とパイプラインの分析 Subcutaneous Drug Delivery Market & Pipeline Insight
出版日: 2015年01月29日 ページ情報: 英文 1800 Pages
概要

革新的な皮下投与剤および投与デバイスは、その多くのメリットから世界的な需要が拡大しています。皮下からの薬剤投与による効力の高さ、徐放性、均一な吸収性は患者に高い治療効果を与えており、副作用を最小限化するためにも、より多くの医師が皮下投与剤を処方しています。新しい製剤も市場への普及を広める大きな要因となっています。また、皮下投与デバイスも技術的に大きく進歩しており、今後シェアを拡大していくでしょう。

当レポートでは、世界の皮下投与剤および投与デバイス市場の動向について調査し、皮下投与のメカニズム、皮下投与市場の概要、市場影響因子の分析、投与デバイスの種類と概要、皮下投与剤の開発動向、上市済み皮下投与剤の概要、競合環境、主要事業者のプロファイルなどをまとめています。

第1章 皮下投与:イントロダクション

第2章 皮下投与のメカニズム

第3章 皮下投与市場の概要

  • 現在の市場シナリオ
  • 皮下投与剤のパイプラインの概要

第4章 皮下投与市場の力学

  • 好意的な市場のパラメーター
  • 臨床面・商業面での課題

第5章 皮下投与デバイス

  • シリンジ
  • 皮下インプラント
  • ペン型シリンジ
  • 自動注射器
  • ポンプ型ドラッグデリバリーシステム

第6章 皮下投与市場の将来の展望

第7章 皮下投与剤の臨床パイプライン:企業・適応症・フェーズ別

  • 未確認
  • 研究
  • 前臨床
  • 臨床
  • 第I相
  • 第I/II相
  • 第II相
  • 第II/III相
  • 第III相
  • 前登録
  • 登録

第8章 上市済み皮下投与剤:臨床的分析

第9章 臨床試験中止・延期の皮下投与剤

  • 進展報告なし
  • 中止
  • 前登録申請取り止め
  • 市場撤退
  • 延期

第10章 競合環境

  • Boehringer Ingelheim
  • Eli Lily
  • Galaxo
  • HMD pharmaceuticals
  • Merck
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Sanofi
  • Teva Pharmaceutical
  • Zogenix

図表

目次

Subcutaneous sites along with intramuscular and intravenous sites are part of parenteral route of drug entry. Maximum pharmacological benefits of a drug could be achieved by deciding effective route of administration depending upon pharmacodynamic properties of the drug to be used. Subcutaneous route is commonly used for the administration of therapeutics into the body for better drug delivery of lipophilic, proteinecious, small molecule drugs. It is characterized by less vasculature, fat rich and less metabolic activity prevents the degradation of drugs resulting in long last effect and higher therapeutic effects.

Subcutaneous sites are versatile routes of administration that can be used for long-term therapeutic benefits. Implants are also placed in this site due to less nerve ending so that pain or discomfort is not produced when such devices are placed at the site. Owing to enormous fat reserves, they are found to have good absorbability for lipid soluble drugs which allows the researchers to design drugs according to the nature of subcutaneous site. Some drugs can't be used via other routes due to difference in their biochemical nature could be administrated subcutaneously. This site is metabolically less active due to which administrated drugs have lesser chances of degradation, enzyme activity and metabolic breakdown as a result of which many drugs could be administrated subcutaneously.

Proteins are important component of several drugs which can't be administrated through other routes like oral, intravenous or intramuscular. Protein based drugs are sensitive towards pH, extreme acidity, alkalinity and limited bioavailability causing limited number of sites for administration. For instance, insulin hormone for the treatment of Diabetes Miletus is a small protein administrated through subcutaneous route. Orally it can't be given due to low pH of stomach which will destroy insulin; intramuscularly it will be absorbed to quickly, while intravenous administration may have potentially high life threatening effects. Also, every year large number of protein based drugs are introduced in market for the treatment of various ailments. Subcutaneous sites are found throughout the body consisting of loose interstitial tissues that may be found in upper arm, anterior thigh surface and lower abdominal portion. These places have been found to be safe and effective for the subcutaneous drug administration.

Numerous benefits provided by innovative subcutaneous drugs and delivery devices have caused increase in their demand across the globe. Higher potency, sustained release and uniform absorption drugs from subcutaneous site has allowed patients to get more therapeutic benefits. More physicians prescribe subcutaneous drugs due to minimized side effects and new formulations are some major factors behind increased market penetration. On the other hand, subcutaneous drug delivery devices have made tremendous increase in technological aspects which is expected to gain more shares in coming years. As a result, it is expected that new innovative products with higher therapeutic capabilities will enter in market in coming years.

“Subcutaneous Drug Delivery Market & Pipeline Insight” Report Findings:

  • Subcutaneous Drug Delivery Market Overview
  • Devices for Subcutaneous Drug Delivery
  • Subcutaneous Drug Delivery Market Future Prospects
  • Subcutaneous Drug Clinical Pipeline by Company, Indication & Phase
  • Global Subcutaneous Drug Clinical Pipeline: 741 Drugs
  • Global Marketed Subcutaneous Drugs: 228 Drugs
  • Marketed Subcutaneous Drug Clinical Insight

Table of Contents

1. Introduction to Subcutaneous Drug Delivery

2. Mechanism of Subcutaneous Drug Delivery

3. Subcutaneous Drug Delivery Market Overview

  • 3.1. Current Market Scenario
  • 3.2. Subcutaneous Drug Delivery Pipeline Overview

4. Subcutaneous Drug Delivery Market Dynamics

  • 4.1. Favorable market Parameters
  • 4.2. Clinical & Commercialization Challenges

5. Devices for Subcutaneous Drug Delivery

  • 5.1. Syringe Based Subcutaneous Drug Delivery
  • 5.2. Subcutaneous Implants
  • 5.3. Pen Systems for Subcutaneous Drug Delivery
  • 5.4. Auto Injectors
  • 5.5. Pump Based Drug Delivery Systems

6. Subcutaneous Drug Delivery Market Future Prospects

7. Subcutaneous Drug Clinical Pipeline by Company, Indication & Phase

  • 7.1. Unknown
  • 7.2. Research
  • 7.3. Preclinical
  • 7.4. Clinical
  • 7.5. Phase-I
  • 7.6. Phase-I/II
  • 7.7. Phase-II
  • 7.8. Phase-II/III
  • 7.9. Phase-III
  • 7.10. Phase: Preregistration
  • 7.11. Phase: Registered

8. Marketed Subcutaneous Drug Clinical Insight

9. Discontinued & Suspended Subcutaneous Drugs in Clinical Trials

  • 9.1. No Development Reported
  • 9.2. Discontinued
  • 9.3. Preregistration-Submission Withdrawal
  • 9.4. Market Withdrawal
  • 9.5. Suspended

10. Competitive Landscape

  • 10.1. Boehringer Ingelheim
  • 10.2. Eli Lily
  • 10.3. Galaxo
  • 10.4. HMD pharmaceuticals
  • 10.5. Merck
  • 10.6. Novartis
  • 10.7. Novo Nordisk
  • 10.8. Pfizer
  • 10.9. Sanofi
  • 10.10. Teva Pharmaceutical
  • 10.11. Zogenix

List of Figures:

  • Figure 1-1: Functions of Skin Tissue
  • Figure 1-2: Different Functions of Skin Layers
  • Figure 1-3: Benefits of Subcutaneous Drug Delivery Site
  • Figure 1-4: Sites for Subcutaneous Drug Administration
  • Figure 1-5: Limitations of Subcutaneous Drug Delivery Site
  • Figure 2-1: External Factors to Increase Absorbability of Subcutaneous Drugs
  • Figure 2-2: Mechanism of Exogenous Insulin Administration at Subcutaneous Site
  • Figure 3-1: Subcutaneous Drug Delivery Pipeline Phase by (%), 2015
  • Figure 3-2: Subcutaneous Drug Delivery Pipeline Phase by (Numbers), 2015
  • Figure 3-3: No Development Reported Subcutaneous Drug Delivery Pipeline Phase by (%), 2015
  • Figure 3-4: No Development Reported Subcutaneous Drug Delivery Pipeline Phase by (Numbers), 2015
  • Figure 3-5: Discontinued Subcutaneous Drug Delivery Pipeline Phase by (%), 2015
  • Figure 3-6: Discontinued Subcutaneous Drug Delivery Pipeline Phase by (Numbers), 2015
  • Figure 3-7: Suspended Subcutaneous Drug Delivery Pipeline Phase by (%), 2015
  • Figure 3-8: Suspended Subcutaneous Drug Delivery Pipeline Phase by (Numbers), 2015
  • Figure 4-1: Drivers for Intramuscular Drug Delivery Market
  • Figure 4-2: Clinical & Commercialization Challenges
  • Figure 5-1: Classification of Subcutaneous Drug Delivery Devices
  • Figure 5-2: Syringe Based Subcutaneous Drug Delivery
  • Figure 5-3: Implant Based Subcutaneous Drug Delivery
  • Figure 5-4: Description of Pen Systems for Subcutaneous Drug Delivery
  • Figure 5-5: Benefits & Drawbacks Pen Systems for Subcutaneous Drug Delivery
  • Figure 5-6: Auto Injectors for Subcutaneous Drug Delivery
  • Figure 5-7: Different Part of Pump Based Subcutaneous Drug Delivery Device

List of Tables:

  • Table 5-1: Comparative Analysis of Different Subcutaneous Drug Delivery Systems
Back to Top